70.70

0.31% -0.22

After Hours: 67.00 -3.70 -5.23%

Ptc Therapeutics Inc (PTCT)

Overview News Price History Option Chain Financials Why PTCT Down? Discussions Forecast

Ptc Therapeutics Inc stock is traded at $70.70, with a volume of 846.06K. It is down -0.31% in the last 24 hours and down -8.88% over the past month. PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The Company views its operations and manages its business in one operating segment: life science.

Previous Close:

$70.92

Open:

$71.19

24h Volume:

846.06K

Relative Volume:

0.55

Market Cap:

$5.68B

Revenue:

$900.66M

Net Income/Loss:

$-453.20M

P/E Ratio:

-11.90

EPS:

-5.94

Net Cash Flow:

$-274.19M

1W Performance:

-2.29%

1M Performance:

-8.88%

6M Performance:

+56.17%

1Y Performance:

+44.49%

1-Day Range:

$69.96

$71.92

1-Week Range:

$69.75

$75.00

52-Week Range:

$35.95

$87.50

Ptc Therapeutics Inc Stock (PTCT) Company Profile

Name

Ptc Therapeutics Inc

Sector

Healthcare (1112)

Industry

Biotechnology (621)

Phone

(908) 222-7000

Address

500 WARREN CORPORATE CENTER DRIVE, WARREN, NJ

Employee

939

Twitter

@PTCBio

Next Earnings Date

2024-11-07

Latest SEC Filings

PTCT's Discussions on Twitter

Compare PTCT vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
PTCT Ptc Therapeutics Inc	70.70	5.69B	900.66M	-453.20M	-274.19M	-5.94
VRTX Vertex Pharmaceuticals Inc	465.02	117.03B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	783.65	82.35B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	833.54	51.64B	3.06B	1.28B	447.35M	19.67
ALNY Alnylam Pharmaceuticals Inc	308.48	42.58B	3.21B	43.57M	221.36M	0.2405
ONC Beone Medicines Ltd Adr	346.42	38.87B	4.98B	69.60M	525.67M	0.5198

Ptc Therapeutics Inc Stock (PTCT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-28-26	Resumed	Barclays	Overweight
Dec-01-25	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Oct-20-25	Initiated	Wells Fargo	Overweight
Jun-17-25	Initiated	Truist	Buy
May-09-25	Upgrade	BofA Securities	Neutral → Buy
May-07-25	Upgrade	Citigroup	Sell → Neutral
Mar-11-25	Upgrade	BofA Securities	Underperform → Neutral
Mar-07-25	Initiated	Scotiabank	Sector Perform
Dec-13-24	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Dec-03-24	Upgrade	RBC Capital Mkts	Sector Perform → Outperform
Oct-10-24	Resumed	Raymond James	Mkt Perform
Sep-04-24	Initiated	Robert W. Baird	Outperform
Aug-26-24	Resumed	UBS	Buy
May-20-24	Upgrade	Raymond James	Underperform → Mkt Perform
Dec-19-23	Downgrade	Morgan Stanley	Equal-Weight → Underweight
Dec-08-23	Initiated	Wells Fargo	Overweight
Oct-30-23	Upgrade	Oppenheimer	Perform → Outperform
Oct-27-23	Downgrade	Citigroup	Neutral → Sell
Oct-06-23	Downgrade	Truist	Buy → Hold
Sep-18-23	Downgrade	Citigroup	Buy → Neutral
Sep-15-23	Downgrade	Raymond James	Outperform → Underperform
Mar-17-23	Initiated	SVB Securities	Market Perform
Dec-14-22	Initiated	Goldman	Sell
Sep-12-22	Initiated	Jefferies	Buy
Sep-09-22	Initiated	Morgan Stanley	Equal-Weight
Sep-01-22	Initiated	Citigroup	Buy
Apr-04-22	Resumed	Cantor Fitzgerald	Overweight
Oct-18-21	Downgrade	BofA Securities	Neutral → Underperform
Apr-26-21	Resumed	Credit Suisse	Neutral
Mar-29-21	Upgrade	RBC Capital Mkts	Underperform → Sector Perform
Feb-12-21	Downgrade	BofA Securities	Buy → Neutral
Jan-05-21	Upgrade	Citigroup	Neutral → Buy
Nov-30-20	Downgrade	RBC Capital Mkts	Sector Perform → Underperform
Oct-30-20	Downgrade	Citigroup	Buy → Neutral
Oct-28-20	Initiated	UBS	Neutral
Oct-07-20	Upgrade	JP Morgan	Neutral → Overweight
Aug-25-20	Initiated	Raymond James	Outperform
Apr-09-20	Upgrade	Citigroup	Neutral → Buy
Feb-20-20	Downgrade	Citigroup	Buy → Neutral
Feb-20-20	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Nov-12-19	Initiated	SunTrust	Buy
May-13-19	Upgrade	BofA/Merrill	Neutral → Buy
Apr-11-19	Initiated	Bernstein	Outperform
Oct-03-18	Upgrade	BofA/Merrill	Underperform → Neutral
Oct-01-18	Initiated	Cantor Fitzgerald	Overweight
Jul-19-18	Initiated	Credit Suisse	Outperform
Jun-18-18	Upgrade	RBC Capital Mkts	Sector Perform → Outperform
Apr-04-18	Downgrade	Barclays	Equal Weight → Underweight
Jan-29-18	Resumed	RBC Capital Mkts	Sector Perform
Nov-16-17	Upgrade	JP Morgan	Underweight → Neutral
Oct-26-17	Downgrade	BofA/Merrill	Neutral → Underperform
Oct-09-17	Downgrade	JP Morgan	Neutral → Underweight

View All

Ptc Therapeutics Inc Stock (PTCT) Latest News

05:34 AM

PTC Therapeutics Withdraws Translarna NDA After FDA Feedback - TipRanks

05:34 AM

05:31 AM

PTC Therapeutics falls after withdrawing muscle disorder drug marketing application - TradingView

05:31 AM

05:07 AM

PTC Therapeutics stock falls after withdrawing Translarna drug application By Investing.com - Investing.com Canada

05:07 AM

05:00 AM

FDA skepticism ends PTC bid to market Duchenne drug Translarna in U.S. - Stock Titan

05:00 AM

11:22 AM

PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release - Finviz

11:22 AM

Feb 10, 2026

PTC Therapeutics (NASDAQ:PTCT) Shareholders Have Earned a 18% CAGR Over the Last Three Years - 富途牛牛

Feb 10, 2026

Feb 09, 2026